Luhan Pharmachem Co., Ltd.
FDAapproves magnetic device system for guiding sentinel lymph node biopsies incertain patients with breast cancer T 07-30
FDAapproves first cancer drug through new oncology review pilot that enablesgreater development efficiencyThe U S F 07-19
On July 13, 2018, the Food and DrugAdministration approved enzalutamide (XTANDI, Astellas Pharma US, Inc ), forpati 07-18
FDAapproves pembrolizumab for advanced cervical cancer with disease progressionduring or after chemotherapyOn June 12 06-14
FDAapproves first biosimilar to Neulasta to help reduce the risk of infectionduring cancer treatment The U S Food 06-06
The U S Food and Drug Administration today approved the first stand-aloneprosthetic iris in the United States, a 05-31
Novel enzyme therapy for adults with PKU who have uncontrolled blood phenylalanine concentrations with current treatment05-29
The U S Food and Drug Administration today approved Aimovig(erenumab-aooe) for the preventive treatment of migraine 05-18
The U S Food and Drug Administration today approved Retacrit (epoetinalfa-epbx) as a biosimilar to Epogen Procrit 05-18
FDApermits marketing of new endoscopic device for treating gastrointestinalbleedingToday(May 7, 2018), the U S Food 05-10
FDAapproves tisagenlecleucel for adults with relapsed or refractory large B-celllymphomaOn May 1, 2018, the Food an 05-04
FDAapproves osimertinib for first-line treatment of metastatic NSCLC with mostcommon EGFR mutat 04-25
Tel: +86 0871 6511 0906 (GMT+8 AM9:00-AM:12:00 PM1:30-PM6:00)
cell phone:188 1221 6310
Fax:0871-63602606
Email: info@luhancn.com
Address:Room 3301,33rd Floor Building B, Vogue Garden Plaza, No.1004 Beijing Road, Kunming, Yunnan Province, P. R. China 650000